Lpath, Inc. Report issue

For profit Phase 1 Phase 2
Founded: San Diego CA United States (2006)
Status: Acquired by Apollo Endosurgery (2016)

Organization Overview

First Clinical Trial
2008
NCT00661414
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 2 Trials (3)

bevacizumab (avastin) (1 trial)

ranibizumab (lucentis) (1 trial)

sonepcizumab (5 trials)

Drugs in Phase 1 Trials (2)

lpathomab (1 trial)

sodium chloride (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Carcinoma, Renal Cell (Phase 2)

Choroidal Neovascularization (Phase 2)

Macular Degeneration (Phase 2)

Neoplasms (Phase 1)

Retinal Detachment (Phase 1)

Vascular Diseases (Phase 1)

Wet Macular Degeneration (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial APIs: 5